Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis
To systematically evaluate the impact of GLP1-RAs on clinical outcomes, including hospitalization rates, surgery, and weight loss, in patients with inflammatory bowel disease (IBD).
Key Findings:
Weight loss achieved with semaglutide (−9.6 kg, 95% CI: −12.0; −7.2), liraglutide (−9.4 kg, 95% CI: −13.0; −5.8), and tirzepatide (−11.8 kg, 95% CI: −18.3; −5.4) after 3 months.
GLP1-RAs associated with lower risk of surgery (logHR: 0.61 [95% CI: 0.44-0.84]; OR: 0.46 [95% CI: 0.32-0.67]).
Sensitivity analysis indicated lower risk of hospitalizations and surgery in obese patients (BMI ≥ 30).
Interpretation:
Patients with IBD and obesity using GLP1-RAs experienced significant weight loss and reduced risks of surgery and hospitalizations, suggesting potential benefits for clinical management.
Limitations:
Findings require confirmation in prospective trials.
Potential risk of intestinal obstruction due to delayed motility.
Possible biases in the included studies may affect the reliability of the findings.
Conclusion:
GLP1-RAs may provide therapeutic benefits for IBD patients, particularly those with obesity, warranting further research.
by Ahmed B Bayoumy, Lindsay M Clarke, Parakkal Deepak, Aakash Desai, Priya Sehgal, uri Gorelik, Haggai Bar-Yoseph, Marie Villumsen, Chris J J Mulder, Dirk J Stenvers, Maarten E Tushuizen, Nanne K H de Boer
